Atossa Genetics Inc. to Raise Approximately $6,220,000 From Institutional Healthcare Investors

20:00 EDT 4 Jun 2015 | Marketwired

SEATTLE, WA -- (Marketwired) -- 06/05/15 -- Atossa Genetics Inc. (NASDAQ: ATOS) (the "Company" or "Atossa") today announced it priced an offering to raise approximately $6,220,000 through the sale of approximately 1.83 million shares of common stock and pre-funded warrants to acquire approximately 3.61 million additional shares of common stock. The offering has been made to two institutional healthcare investors, with the shares being sold at a price of $1.15 per share, and the pre-funded warrants being sold at a price of $1.14 per warrant, payable at closing.

Roth Capital Partners served as lead placement agent for the offering. Dawson James Securities, Inc. served as co-placement agent for the offering. After placement agent fees and estimated offering expenses payable by the company, the company expects to receive net proceeds of approximately $5.6 million. The offering is expected to close on or about June 10, 2015, subject to customary closing conditions.

Atossa intends to use the net proceeds from the offering for general corporate purposes, funding its future clinical trials and for general and administrative expenses.

The securities are being offered pursuant to a shelf registration statement (File No. 333-192390), including a base prospectus, which was declared effective by the United States Securities and Exchange Commission (the "SEC") on November 29, 2013. A prospectus supplement relating to the offering will be filed with the SEC and will be available on the SEC's website at

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. Copies of the prospectus supplement and accompanying base prospectus relating to this offering may be obtained from Roth Capital Partners, LLC, 888 San Clemente, Newport Beach, CA 92660, (800) 678-9147 or email: or by accessing the SEC's website,

Steven C. Quay, M.D., Ph.D. President & Chief Executive Officer Atossa Genetics Inc. Phone: (800) 351-3902 and Kyle Guse Chief Financial Officer, General Counsel and Secretary Atossa Genetics Inc. Phone: (800) 351-3902 Scott Gordon CorProminence LLC 377 Oak Street Concourse 2 Garden City, NY 11530 Office: 516.222.2560 NEXT ARTICLE

More From BioPortfolio on "Atossa Genetics Inc. to Raise Approximately $6,220,000 From Institutional Healthcare Investors "

Quick Search


Relevant Topics

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...